Cover Image
市場調查報告書

糖尿病視網膜病變:開發中產品分析

Diabetic Retinopathy - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 192559
出版日期 內容資訊 英文 195 Pages
訂單完成後即時交付
價格
Back to Top
糖尿病視網膜病變:開發中產品分析 Diabetic Retinopathy - Pipeline Review, H2 2017
出版日期: 2017年11月14日 內容資訊: 英文 195 Pages
簡介

糖尿病視網膜病變是糖尿病併發症的一種,會對眼睛帶來負面影響,主要的症狀有視野中浮現黑點和細紋(飛蚊症),及視力模糊、視力變動、視力降低、色覺認識障礙等。致病的危險因子有糖尿病和高血壓、高膽固醇症、妊娠、抽煙等。

本報告提供全球各國治療糖尿病視網膜病變所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

糖尿病視網膜病變概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9908IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Pipeline Review, H2 2017, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.

Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 8, 6, 1, 38, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 6 molecules, respectively.

Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Diabetic Retinopathy - Overview
    • Diabetic Retinopathy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Diabetic Retinopathy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Diabetic Retinopathy - Companies Involved in Therapeutics Development
    • Abzena Plc
    • Acucela Inc
    • Aerie Pharmaceuticals Inc
    • Aerpio Therapeutics Inc
    • Antisense Therapeutics Ltd
    • AntriaBio Inc
    • BCN Peptides SA
    • Boehringer Ingelheim GmbH
    • Charlesson LLC
    • Coherus BioSciences Inc
    • Crinetics Pharmaceuticals Inc
    • Dimerix Bioscience Pty Ltd
    • Dynamis Therapeutics Inc
    • EyeGene Inc
    • F. Hoffmann-La Roche Ltd
    • Foresee Pharmaceuticals LLC
    • Icon Bioscience Inc
    • Islet Sciences Inc
    • Kodiak Sciences Inc
    • Kowa Co Ltd
    • Lupin Ltd
    • M's Science Corp
    • Mabion SA
    • Navigen Inc
    • Nemus Bioscience Inc
    • Oculis ehf
    • Ohr Pharmaceutical Inc
    • PanOptica Inc
    • Profarma
    • Promedior Inc
    • Regeneron Pharmaceuticals Inc
    • Ribomic Inc
    • Strongbridge Biopharma plc
    • Sylentis SAU
    • ThromboGenics NV
    • VESSL Therapeutics Ltd
  • Diabetic Retinopathy - Drug Profiles
    • (irbesartan + propagermanium) - Drug Profile
    • A-717 - Drug Profile
    • AB-402 - Drug Profile
    • AC-301 - Drug Profile
    • aflibercept - Drug Profile
    • aflibercept biosimilar - Drug Profile
    • AKB-9778 - Drug Profile
    • Antisense RNAi Oligonucleotide to Inhibit ProRenin Receptor for Uveitis and Diabetic Retinopathy - Drug Profile
    • APTA-1004 - Drug Profile
    • Aptamers for Diabetic Retinopathy - Drug Profile
    • AQA-001 - Drug Profile
    • AR-13154 - Drug Profile
    • atesidorsen sodium - Drug Profile
    • BI-1467335 - Drug Profile
    • BI-690517 - Drug Profile
    • Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile
    • BNN-27 - Drug Profile
    • Cell Therapy for Diabetic Retinopathy - Drug Profile
    • CLT-005 - Drug Profile
    • CLT-020 - Drug Profile
    • CRN-00808 - Drug Profile
    • cyclosporine - Drug Profile
    • Cyndacel-M - Drug Profile
    • DRGT-109 - Drug Profile
    • DT-23552 - Drug Profile
    • DYN-12 - Drug Profile
    • E-1086 - Drug Profile
    • EG-Mirotin - Drug Profile
    • emixustat hydrochloride - Drug Profile
    • fenofibrate - Drug Profile
    • FP-008 - Drug Profile
    • Gene Therapy for Diabetic Retinopathy - Drug Profile
    • GLY-230 - Drug Profile
    • HCB-1019 - Drug Profile
    • IVMED-60 - Drug Profile
    • JP-153 - Drug Profile
    • KSI-301 - Drug Profile
    • magacizumab - Drug Profile
    • Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile
    • MS-553 - Drug Profile
    • NB-2222 - Drug Profile
    • NM-108 - Drug Profile
    • OC-410 - Drug Profile
    • ocriplasmin - Drug Profile
    • OCU-200 - Drug Profile
    • OCX-063 - Drug Profile
    • PAN-90806 - Drug Profile
    • Peptagon - Drug Profile
    • PF-07 - Drug Profile
    • PRM-167 - Drug Profile
    • Protein for Oncology, Ophthalmology and Metabolic Disorders - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • RBM-008 - Drug Profile
    • Recombinant Protein for Oncology, Diabetic Retinopathy and Retinopathy Of Prematurity - Drug Profile
    • Recombinant Protein to Activate Caspases for Diabetic Retinopathy, Age Related Macular Degeneration and Solid Tumor - Drug Profile
    • Recombinant Proteins to Inhibit VEGFA for Diabetic Retinopathy - Drug Profile
    • Resolvine ER - Drug Profile
    • ripasudil - Drug Profile
    • RO-5461111 - Drug Profile
    • RT-001 - Drug Profile
    • RT-002 - Drug Profile
    • SBT-200 - Drug Profile
    • Small Molecules to Inhibit ARF6 for Macular Degeneration and Diabetic Retinopathy - Drug Profile
    • somatostatin - Drug Profile
    • squalamine lactate - Drug Profile
    • Stem Cell Therapy for Diabetic Retinopathy - Drug Profile
    • Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders - Drug Profile
    • SYL-136001v10 - Drug Profile
    • THR-687 - Drug Profile
    • Vaxier-001 - Drug Profile
    • veldoreotide - Drug Profile
    • Wnt-001 - Drug Profile
  • Diabetic Retinopathy - Dormant Projects
  • Diabetic Retinopathy - Discontinued Products
  • Diabetic Retinopathy - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Diabetic Retinopathy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Diabetic Retinopathy - Pipeline by Abzena Plc, H2 2017
  • Diabetic Retinopathy - Pipeline by Acucela Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by Aerpio Therapeutics Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by Antisense Therapeutics Ltd, H2 2017
  • Diabetic Retinopathy - Pipeline by AntriaBio Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by BCN Peptides SA, H2 2017
  • Diabetic Retinopathy - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Diabetic Retinopathy - Pipeline by Charlesson LLC, H2 2017
  • Diabetic Retinopathy - Pipeline by Coherus BioSciences Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by Crinetics Pharmaceuticals Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by Dimerix Bioscience Pty Ltd, H2 2017
  • Diabetic Retinopathy - Pipeline by Dynamis Therapeutics Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by EyeGene Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Diabetic Retinopathy - Pipeline by Foresee Pharmaceuticals LLC, H2 2017
  • Diabetic Retinopathy - Pipeline by Icon Bioscience Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by Islet Sciences Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by Kodiak Sciences Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by Kowa Co Ltd, H2 2017
  • Diabetic Retinopathy - Pipeline by Lupin Ltd, H2 2017
  • Diabetic Retinopathy - Pipeline by M's Science Corp, H2 2017
  • Diabetic Retinopathy - Pipeline by Mabion SA, H2 2017
  • Diabetic Retinopathy - Pipeline by Navigen Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by Nemus Bioscience Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by Oculis ehf, H2 2017
  • Diabetic Retinopathy - Pipeline by Ohr Pharmaceutical Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by PanOptica Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by Profarma, H2 2017
  • Diabetic Retinopathy - Pipeline by Promedior Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by Ribomic Inc, H2 2017
  • Diabetic Retinopathy - Pipeline by Strongbridge Biopharma plc, H2 2017
  • Diabetic Retinopathy - Pipeline by Sylentis SAU, H2 2017
  • Diabetic Retinopathy - Pipeline by ThromboGenics NV, H2 2017
  • Diabetic Retinopathy - Pipeline by VESSL Therapeutics Ltd, H2 2017
  • Diabetic Retinopathy - Dormant Projects, H2 2017
  • Diabetic Retinopathy - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Diabetic Retinopathy - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Diabetic Retinopathy - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Diabetic Retinopathy - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Diabetic Retinopathy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top